All In MedTech

FDA Clearance Tracker · P100018-S034

Pipeline Vantage Embolization Device with Shield Technology

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 15, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 15, 2023

Approved

Time to decision

718 days

Received Sep 27, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P100018-S034
Device name
Pipeline Vantage Embolization Device with Shield Technology
Applicant location
Irvine, CA
Received
Sep 27, 2021
Decided
Sep 15, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P100018

Device type

Device class
Class III

Every decision under product code OUT

FDA's approval statement

As written in FDA's record.

Approval for a new neurovascular flow-diverting stent and delivery system in the Pipeline product family.

Source documents

Other decisions for Micro Therapeutics, Inc. d/b/a ev3 Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.